title: Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.
abstract: OBJECTIVE
  To assess the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) test for active tuberculosis (TB) in HIV adults, and its variation over time in patients on antiretroviral therapy (ART) and/or isoniazide preventive therapy (IPT).
  
  
  METHODS
  Transversal study and cohort nested in the Temprano ANRS 12136 randomized controlled trial assessing benefits of initiating ART earlier than currently recommended by World Health Organization, with or without a 6-month IPT. Performance of QFT-GIT for detecting active TB at baseline in the first 50% participants, and 12-month incidence of conversion/reversion in the first 25% participants were assessed. QFT-GIT threshold for positivity was 0.35 IU/ml.
  
  
  RESULTS
  Among the 975 first participants (median baseline CD4 count 383/mm3, positive QFT-GIT test 35%), 2.7% had active TB at baseline. QFT-GIT sensitivity, specificity, positive and negative predictive value for active TB were 88.0%, 66.6%, 6.5% and 99.5%. For the 444 patients with a second test at 12 months, rates for conversion and reversion were 9.3% and 14%. Reversion was more frequent in patients without ART and younger patients. IPT and early ART were not associated with reversion/conversion.
  
  
  CONCLUSIONS
  A negative QFT-GIT could rule out active TB in HIV-infected adults not severely immunosuppressed, thus avoiding repeated TB testing and accelerating diagnosis and care for other diseases.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT00495651.
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Danel
authors.affiliation: CeDReS, CHU Treichville, Abidjan, Côte d'Ivoire.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Kabran
authors.affiliation: PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; CeDReS, CHU Treichville, Abidjan, Côte d'Ivoire.
authors.forename: André
authors.initials: A
authors.lastname: Inwoley
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
authors.forename: Anani
authors.initials: A
authors.lastname: Badje
authors.affiliation: Service de Bactériologie, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris, Garches, France; EA3647, Université de Versailles St Quentin en Yvelines, Montigny le Bretonneux, France.
authors.forename: Jean Louis
authors.initials: JL
authors.lastname: Herrmann
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France; Service des Maladies Infectieuses et Tropicales, CHU Treichville, Abidjan, Côte d'Ivoire.
authors.forename: Raoul
authors.initials: R
authors.lastname: Moh
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Lecarrou
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Gabillard
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
authors.forename: Jean Baptiste
authors.initials: JB
authors.lastname: Ntakpe
authors.affiliation: PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire.
authors.forename: Nina
authors.initials: N
authors.lastname: Deschamps
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Ouattara
authors.affiliation: Département de Maladies Infectieuses et Tropicales, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris, Garches, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Perronne
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France; Service des Maladies Infectieuses et Tropicales, CHU Treichville, Abidjan, Côte d'Ivoire.
authors.forename: Serge
authors.initials: S
authors.lastname: Eholie
authors.affiliation: INSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Anglaret
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D007560:Cote d'Ivoire; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis*; D007538:Isoniazid / Q000494:pharmacology; D008297:Male; D014376:Tuberculosis / Q000150:complications* / Q000175:diagnosis* / Q000517:prevention & control
chemical_list: D019380:Anti-HIV Agents; D007371:Interferon-gamma; D007538:Isoniazid